2022-503084-15-00
招募中
1 期
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer
Deutsches Krebsforschungszentrum (DKFZ)4 个研究点 分布在 1 个国家目标入组 77 人2023年11月22日
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Deutsches Krebsforschungszentrum (DKFZ)
- 入组人数
- 77
- 试验地点
- 4
- 状态
- 招募中
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
KKE Translational Immunology, University Hospital Tuebingen
Scientific
Deutsches Krebsforschungszentrum (DKFZ)
入排标准
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
未指定
研究点 (4)
Loading locations...
相似试验
尚未招募
1 期
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra-Peptide in healthy volunteersAcromegalyDRKS00032263niversität Heidelberg vertreten durch das Universitätsklinikum95
已完成
1 期
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra peptide in healthy volunteers2024-514225-30-00Universitaetsklinikum Heidelberg AöR45
招募中
1 期
A First-in-Human clinical trial assessing safety of ES2B-C001 with or without Montanide in patients with HER2 expressing metastatic breast cancer.2024-516333-12-00Expres2ion Biotechnologies ApS27
已完成
不适用
A phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG232 in adult subjects with advanced solid tumors or multiple myelomasolide tumorentumor in the organsNL-OMON44939Amgen42
尚未招募
1 期
A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natural killer cells) in patients with relapsed/refractory diffuse large B-cell lymphoma2024-511843-24-00Emercell SAS10